COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort

Abstract: Journal Pre-proof COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort Marius Ahm Stauning, Dogukan Jesper Gür, Christian Torp-Pedersen, Jens Tingleff PII: S1198-743X(23)00203-3 DOI: https://doi.org/10.1016/j.cmi.2023.04.028 Reference: CMI 3282 To appear in: Clinical Microbiology and Infection Received Date: 3 January 2023 Revised Date: 25 March 2023 Accepted Date: 26 April 2023 Please cite this article as: Stauning MA, Gür DJ, Torp-Pedersen C, Tingleff J, COVID-19 mortality among selective serotonin reuptake inhibitor users - Results from a nationwide cohort Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2023.04.028. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2023 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. Titlepage Original article: COVID-19 mortality among selective serotonin reuptake inhibitor users Results from a nationwide cohort re -p r oo f Marius Ahm Stauning 1 * Dogukan Jesper Gür 2 * Christian Torp-Pedersen3, 4 Jens Tingleff 2, 5 ur na lP 1) Department of Clinical Microbiology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark 2) Department of Emergency Medicine, Copenhagen University Hospital - Amager and Hvidovre , Copenhagen, Denmark 3) Department of Cardiology, Copenhagen University Hospital – North Zealand, Hillerød, Denmark. 4) Department of Public Health, University of Copenhagen, Denmark 5) Department of Clinical Medicine, University of Copenhagen, Denmark. Jo *) These authors contributed equally to the study and share first authorship. Corresponding author: Marius Ahm Stauning, M.D Department of Clinical Microbiology, Copenhagen University Hospital – Rigshospitalet Blegdamsvej 9, 2100 Copenhagen Denmark Email: marius.ahm.stauning@regionh.dk Phone: +45 60 89 88 23 Abstract Objective: To examine differences in mortality and/or severe acute respiratory syndrome between selective serotonin reuptake inhibitor- (SSRI) users and non-SSRI-users up to 60 days after a positive severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) real-time reverse transcription-polymerase chain reaction (PCR) test. Methods: Retrospective cohort study including all Danish residents above the age of eighteen with oo f a positive SARS- CoV-2 PCR test from February 26th, 2020, to October 5th2021. The follow-up re -p r period was 60 days. The primary outcome was all-cause mortality, and the secondary outcome was severe acute respiratory syndrome. Exposure of interest was SSRI-use. Differences between SSRI- lP users and non-users were examined with Cox Regression. ur na Results: 286447 SARS-CoV-2 positive individuals were identified, and 7113 met the criteria for SSRI-use. SSRI-users had a mean age of 50.4 years, and 34% were male. Non-SSRI users had a mean age of 41.4 years, and 50 % were male. Similar vaccination frequency was seen..